{
    "hands_on_practices": [
        {
            "introduction": "Understanding a disease often begins at the cellular level. This practice connects the molecular biology of Human Papillomavirus (HPV) to a visible pattern under the microscope, demonstrating how a virus can hijack the cell's machinery. By analyzing the distribution of the proliferation marker Ki-67, you will learn to distinguish between normal cell turnover and the uncontrolled growth characteristic of a high-grade lesion ().",
            "id": "4468763",
            "problem": "A vulvar punch biopsy from a patient aged $45$ years shows stratified squamous epithelium with architectural and cytologic atypia. Immunohistochemistry for the proliferation marker Ki-67 demonstrates labeling indices of $10\\%$, $35\\%$, and $70\\%$ in the basal, mid, and superficial epithelial layers, respectively. Use the following foundational facts to reason to the most likely diagnosis and etiologic association: Ki-67 is expressed in actively cycling cells during the $G_1$, $S$, $G_2$, and $M$ phases but is absent in quiescent $G_0$ cells; in normal stratified squamous epithelium, cycling cells are mainly restricted to the basal and parabasal layers; deregulation of cell-cycle checkpoints via loss of tumor suppressor function (for example, p$53$ and retinoblastoma protein (pRb)) permits suprabasal cells to re-enter the cell cycle; high-risk Human Papillomavirus (HPV) oncoproteins E$6$ and E$7$ inactivate p$53$ and pRb, respectively, driving unscheduled $S$-phase entry and expanded proliferative compartments. Based on these principles and the given Ki-67 distribution, which option best integrates the lesion grade and HPV association?\n\nA. Low-grade squamous intraepithelial lesion (LSIL, condylomatous changes), associated with low-risk Human Papillomavirus (HPV), with proliferation confined to the basal/parabasal layers\n\nB. High-grade squamous intraepithelial lesion (HSIL, usual-type Vulvar Intraepithelial Neoplasia (VIN)), associated with high-risk Human Papillomavirus (HPV), characterized by diffuse cell-cycle deregulation and suprabasal proliferation\n\nC. Differentiated Vulvar Intraepithelial Neoplasia (dVIN), Human Papillomavirus (HPV)-independent, often driven by p$53$ mutation, with proliferation largely restricted to basal layers\n\nD. Reactive squamous hyperplasia (lichen simplex chronicus), Human Papillomavirus (HPV)-independent, with Ki-67 labeling limited to basal/parabasal compartments\n\nE. Extramammary Paget disease of vulva, Human Papillomavirus (HPV)-independent, with low proliferative indices predominantly in the basal layer",
            "solution": "The user has provided a clinical pathology problem and requires a solution derived from first principles, including a validation of the problem statement and a detailed evaluation of each option.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   Patient age: $45$ years\n*   Biopsy type: Vulvar punch biopsy\n*   Histopathology: Stratified squamous epithelium with architectural and cytologic atypia.\n*   Immunohistochemistry (IHC) for Ki-67:\n    *   Basal layer labeling index: $10\\%$\n    *   Mid epithelial layer labeling index: $35\\%$\n    *   Superficial epithelial layer labeling index: $70\\%$\n*   Foundational Facts:\n    1.  Ki-67 is expressed in actively cycling cells (phases $G_1$, $S$, $G_2$, and $M$) but is absent in quiescent ($G_0$) cells.\n    2.  In normal stratified squamous epithelium, cycling cells are mainly restricted to the basal and parabasal layers.\n    3.  Deregulation of cell-cycle checkpoints, via loss of tumor suppressor function (e.g., p$53$ and retinoblastoma protein, pRb), permits suprabasal cells to re-enter the cell cycle.\n    4.  High-risk Human Papillomavirus (HPV) oncoproteins E$6$ and E$7$ inactivate p$53$ and pRb, respectively.\n    5.  This inactivation by high-risk HPV drives unscheduled $S$-phase entry and an expanded proliferative compartment.\n\n**Step 2: Validate Using Extracted Givens**\n\nThe problem is subjected to validation against the specified criteria.\n\n*   **Scientifically Grounded:** The problem is firmly rooted in the established principles of molecular pathology, cell biology, and virology. The roles of Ki-67, p$53$, pRb, and HPV oncoproteins E$6$ and E$7$ in cell cycle regulation and carcinogenesis are fundamental concepts in oncology.\n*   **Well-Posed:** The problem provides specific data (Ki-67 distribution) and the exact theoretical framework (foundational facts) needed to interpret that data. It asks for the most likely diagnosis that integrates these two elements, which allows for a unique and logical conclusion.\n*   **Objective:** The language is technical and precise (e.g., \"cytologic atypia,\" \"Ki-67 labeling indices\"). It is free of subjective or ambiguous terminology.\n*   **Complete and Consistent:** The problem is self-contained. The provided Ki-67 indices ($10\\%$, $35\\%$, $70\\%$) clearly demonstrate a specific pathological pattern—an expanded and abnormal proliferative compartment—which is the key finding to be explained by the provided principles. While the inverted gradient (higher proliferation superficially) is a strong representation, the essential information is the high suprabasal proliferation, which is not contradictory and is sufficient for a diagnosis.\n*   **Realistic and Feasible:** The clinical scenario—a $45$-year-old patient with a vulvar lesion showing atypia—is common. The use of IHC for Ki-67 to assess proliferation is a standard diagnostic and research tool in pathology. The described biological mechanisms are central to the pathogenesis of HPV-related neoplasia.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically sound, well-posed, objective, and internally consistent. The solution process may proceed.\n\n### Solution Derivation\n\nThe problem requires a diagnosis based on the integration of histopathologic findings (atypia), specific immunohistochemical data (Ki-67 indices), and fundamental biological principles.\n\n1.  **Analyze the Normal State:** The foundational facts establish that in normal stratified squamous epithelium, cell proliferation (marked by Ki-67) is restricted to the basal and parabasal layers. As cells mature and move towards the surface, they exit the cell cycle (enter $G_0$) and cease to express Ki-67. A normal Ki-67 pattern would show significant labeling at the base and little to no labeling in the mid and superficial layers.\n\n2.  **Analyze the Pathological Findings:** The biopsy shows \"architectural and cytologic atypia,\" which signifies a pre-malignant or neoplastic process. The crucial datum is the Ki-67 distribution: $10\\%$ in the basal layer, $35\\%$ in the mid layer, and $70\\%$ in the superficial layer. This pattern is pathologically abnormal in two ways:\n    *   **Suprabasal Proliferation:** There is significant proliferation in the mid ($35\\%$) and superficial ($70\\%$) layers, a clear deviation from the normal state. This is referred to as an \"expanded proliferative compartment.\"\n    *   **Loss of Polarity:** The proliferation is not only expanded but also disordered. In a normally maturing epithelium, proliferation decreases with distance from the basal layer. Here, it increases, indicating a complete loss of normal cell cycle control concurrent with epithelial maturation.\n\n3.  **Apply the Provided Principles:** The foundational facts provide a direct mechanistic explanation for this observation.\n    *   Fact #$3$ states that loss of tumor suppressor function (p$53$, pRb) allows suprabasal cells to re-enter the cell cycle.\n    *   Facts #$4$ and #$5$ state that high-risk HPV oncoproteins, E$6$ and E$7$, cause this exact loss of function by inactivating p$53$ and pRb, respectively, leading to \"unscheduled S-phase entry and expanded proliferative compartments.\"\n\n4.  **Synthesize a Conclusion:** The observed Ki-67 pattern is a direct manifestation of the biological effects of high-risk HPV. The virus forces cells that should be terminally differentiating and quiescent to remain in the cell cycle, leading to high levels of proliferation throughout the epithelial thickness. A squamous intraepithelial lesion characterized by significant atypia and this pattern of diffuse, disorganized, full-thickness proliferation driven by high-risk HPV is defined as a High-Grade Squamous Intraepithelial Lesion (HSIL). In the vulva, this is also known as usual-type Vulvar Intraepithelial Neoplasia (uVIN).\n\n### Option-by-Option Analysis\n\n*   **A. Low-grade squamous intraepithelial lesion (LSIL, condylomatous changes), associated with low-risk Human Papillomavirus (HPV), with proliferation confined to the basal/parabasal layers**\n    *   **Analysis:** This option is incorrect. LSIL is characterized by low-grade atypia and, crucially, proliferation that is largely confined to the lower one-third of the epithelium. The given Ki-67 data show high proliferation rates of $35\\%$ and $70\\%$ in the mid and superficial layers, respectively, directly contradicting the defining features of LSIL.\n    *   **Verdict:** Incorrect.\n\n*   **B. High-grade squamous intraepithelial lesion (HSIL, usual-type Vulvar Intraepithelial Neoplasia (VIN)), associated with high-risk Human Papillomavirus (HPV), characterized by diffuse cell-cycle deregulation and suprabasal proliferation**\n    *   **Analysis:** This option aligns perfectly with the derived conclusion. The diagnosis of HSIL accounts for the \"architectural and cytologic atypia.\" Its association with high-risk HPV explains the mechanism of cell-cycle deregulation. The description \"diffuse cell-cycle deregulation and suprabasal proliferation\" is an exact characterization of the state demonstrated by the Ki-67 proliferative indices of $35\\%$ and $70\\%$ in the upper epithelial layers.\n    *   **Verdict:** Correct.\n\n*   **C. Differentiated Vulvar Intraepithelial Neoplasia (dVIN), Human Papillomavirus (HPV)-independent, often driven by p$53$ mutation, with proliferation largely restricted to basal layers**\n    *   **Analysis:** This option is incorrect. While dVIN is an HPV-independent form of vulvar neoplasia, its characteristic proliferation pattern is expansion within the basal and parabasal layers, with overlying cells showing maturation (albeit atypical). It does *not* typically feature high proliferative rates in the superficial layers. The observed Ki-67 pattern is the antithesis of that seen in classic dVIN.\n    *   **Verdict:** Incorrect.\n\n*   **D. Reactive squamous hyperplasia (lichen simplex chronicus), Human Papillomavirus (HPV)-independent, with Ki-67 labeling limited to basal/parabasal compartments**\n    *   **Analysis:** This option is incorrect. Reactive hyperplasia is a benign, non-neoplastic condition. It lacks the \"cytologic atypia\" mentioned in the problem stem. Furthermore, while there is an increase in proliferation, it remains orderly and confined to the basal/parabasal compartment, unlike the widespread proliferation seen in this case.\n    *   **Verdict:** Incorrect.\n\n*   **E. Extramammary Paget disease of vulva, Human Papillomavirus (HPV)-independent, with low proliferative indices predominantly in the basal layer**\n    *   **Analysis:** This option is incorrect. Extramammary Paget disease is an intraepidermal adenocarcinoma, a malignancy of glandular cells, not a squamous intraepithelial lesion. The histopathology would involve Paget cells, which are not described. The problem describes atypia within the \"stratified squamous epithelium,\" indicating a primary squamous process. The described Ki-67 pattern is not characteristic of Paget disease or the surrounding squamous epithelium.\n    *   **Verdict:** Incorrect.",
            "answer": "$$\\boxed{B}$$"
        },
        {
            "introduction": "Diagnostic tests are powerful, but they are not infallible. This exercise moves beyond a simple 'positive' or 'negative' result to explore the quantitative confidence a test provides. Using the principles of Bayes' theorem, you will calculate the post-test probability of a disease, learning how a pathologist combines pre-existing clinical suspicion with a new piece of evidence—in this case, a p$16$ immunohistochemical stain ().",
            "id": "4468826",
            "problem": "A surgical pathology service evaluates vulvar biopsies for human papillomavirus (HPV)-associated high-grade squamous intraepithelial lesion (HSIL). As part of ancillary testing, p16 immunohistochemistry (IHC) is performed, where a \"block-positive\" result is considered a positive test for HPV-associated HSIL. In a cohort of morphologically ambiguous vulvar squamous intraepithelial lesions referred to a high-risk evaluation clinic, the pretest prevalence (pretest probability) of HPV-associated HSIL is estimated to be $0.30$. Independent validation studies for p16 IHC in this context report a sensitivity of $0.90$ and a specificity of $0.85$ for detecting HPV-associated HSIL.\n\nStarting from the core definitions of conditional probability and well-tested clinical epidemiologic quantities, namely sensitivity, specificity, positive predictive value, and negative predictive value, and using the law of total probability together with Bayes' theorem, derive an analytic expression for the post-test probability of HPV-associated HSIL given a positive p16 IHC result. Then, using the provided values, compute the numerical value of this post-test probability.\n\nExpress your final answer as a decimal fraction, rounded to four significant figures. Do not use a percentage sign.",
            "solution": "The problem as stated is subjected to validation.\n\n### Step 1: Extract Givens\n- The pretest prevalence (pretest probability) of HPV-associated HSIL is $0.30$.\n- The sensitivity of p16 IHC for detecting HPV-associated HSIL is $0.90$.\n- The specificity of p16 IHC for detecting HPV-associated HSIL is $0.85$.\n- A \"block-positive\" p16 IHC result is considered a positive test.\n- The task is to derive an analytic expression for the post-test probability of HPV-associated HSIL given a positive p16 IHC result, and then to compute its numerical value, rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n- **Scientifically Grounded**: The problem is grounded in the established principles of clinical epidemiology and biostatistics. The use of prevalence, sensitivity, specificity, and Bayes' theorem to calculate post-test probability (positive predictive value) is a standard and fundamental method in evidence-based medicine and pathology. The values provided for prevalence, sensitivity, and specificity are realistic for the described clinical scenario.\n- **Well-Posed**: The problem is well-posed. It provides all necessary data—prevalence, sensitivity, and specificity—to uniquely determine the desired quantity, which is the positive predictive value. The objective is clearly stated.\n- **Objective**: The problem is stated in precise, objective, and unbiased language, using standard terminology from pathology and statistics.\n\n### Step 3: Verdict and Action\nThe problem is valid. It is scientifically sound, well-posed, and objective. There are no identifiable flaws. The solution process may proceed.\n\n### Derivation and Calculation\n\nThe problem requires the derivation and calculation of the post-test probability of having a disease given a positive test result. This quantity is formally known as the Positive Predictive Value (PPV).\n\nLet us define the following events:\n- $D$: The event that a patient has HPV-associated HSIL (the \"disease\").\n- $\\neg D$: The event that a patient does not have HPV-associated HSIL.\n- $T$: The event that the p16 IHC test is positive.\n- $\\neg T$: The event that the p16 IHC test is negative.\n\nFrom the problem statement, we are given the following probabilities:\n1.  The pretest probability, or prevalence, of the disease is $P(D) = 0.30$.\n2.  The sensitivity of the test is the probability of a positive test result given that the disease is present: $P(T|D) = 0.90$.\n3.  The specificity of the test is the probability of a negative test result given that the disease is absent: $P(\\neg T|\\neg D) = 0.85$.\n\nFrom these givens, we can deduce two other necessary probabilities:\n- The probability of not having the disease is $P(\\neg D) = 1 - P(D) = 1 - 0.30 = 0.70$.\n- The probability of a positive test result given that the disease is absent (the false positive rate) is $P(T|\\neg D) = 1 - P(\\neg T|\\neg D) = 1 - 0.85 = 0.15$.\n\nThe quantity we wish to find is the post-test probability of disease given a positive test, which is the conditional probability $P(D|T)$.\n\nAccording to the definition of conditional probability, Bayes' theorem states:\n$$P(D|T) = \\frac{P(T|D)P(D)}{P(T)}$$\n\nThe term in the denominator, $P(T)$, is the total probability of a positive test result. This can be calculated using the law of total probability, which considers the two mutually exclusive scenarios in which a positive test can occur: the patient has the disease, or the patient does not have the disease.\n$$P(T) = P(T \\cap D) + P(T \\cap \\neg D)$$\n\nUsing the definition of conditional probability again, $P(A \\cap B) = P(A|B)P(B)$, we can expand these terms:\n$$P(T) = P(T|D)P(D) + P(T|\\neg D)P(\\neg D)$$\n\nSubstituting this expansion for $P(T)$ back into the Bayes' theorem formula gives the complete expression for $P(D|T)$:\n$$P(D|T) = \\frac{P(T|D)P(D)}{P(T|D)P(D) + P(T|\\neg D)P(\\neg D)}$$\n\nThis is the required analytic expression. We can also express it in terms of the clinical epidemiological quantities: prevalence ($Prev$), sensitivity ($Sens$), and specificity ($Spec$).\n$$PPV = P(D|T) = \\frac{Sens \\cdot Prev}{Sens \\cdot Prev + (1 - Spec) \\cdot (1 - Prev)}$$\n\nNow, we substitute the numerical values provided in the problem statement into this derived expression:\n- $Prev = P(D) = 0.30$\n- $Sens = P(T|D) = 0.90$\n- $Spec = P(\\neg T|\\neg D) = 0.85$\n\nSo, $(1 - Prev) = P(\\neg D) = 0.70$ and $(1 - Spec) = P(T|\\neg D) = 0.15$.\n\n$$P(D|T) = \\frac{(0.90) \\cdot (0.30)}{(0.90) \\cdot (0.30) + (0.15) \\cdot (0.70)}$$\n\nFirst, we calculate the numerator and the terms in the denominator:\n- Numerator: $0.90 \\times 0.30 = 0.27$. This is the probability of a true positive result.\n- Denominator term 1: $0.90 \\times 0.30 = 0.27$.\n- Denominator term 2: $0.15 \\times 0.70 = 0.105$. This is the probability of a false positive result.\n\n$$P(D|T) = \\frac{0.27}{0.27 + 0.105}$$\n$$P(D|T) = \\frac{0.27}{0.375}$$\n\nPerforming the final division:\n$$P(D|T) =\n0.72$$\n\nThe problem requires the answer to be expressed as a decimal fraction rounded to four significant figures. Therefore, $0.72$ is written as $0.7200$.",
            "answer": "$$\\boxed{0.7200}$$"
        },
        {
            "introduction": "A cancer diagnosis is the first step; determining its extent, or 'stage', is the critical next step that guides treatment and predicts prognosis. This practice simulates the work of a tumor board, where pathologists and clinicians apply standardized criteria to a clinical case. You will use the International Federation of Gynecology and Obstetrics (FIGO) guidelines to stage a vulvar carcinoma, a process that requires meticulous attention to anatomical detail and a systematic approach ().",
            "id": "4468730",
            "problem": "A $62$-year-old patient presents with a primary vulvar lesion that is biopsy-proven squamous cell carcinoma. On examination, the lesion is centered on the right labia majora, measures approximately $3.2$ $\\mathrm{cm}$ in greatest dimension, and shows stromal invasion deeper than $1$ $\\mathrm{mm}$. There is contiguous mucosal extension to the ipsilateral lower third of the vagina, with no involvement of the upper vagina, urethral meatus, bladder, rectal mucosa, or pelvic bone. The lesion is mobile. Palpation and ultrasound of the groin show no enlarged inguinofemoral nodes; sentinel lymph node biopsy returns negative for metastasis. Pelvic magnetic resonance imaging (MRI) confirms no pelvic wall involvement and no distant disease.\n\nUsing the principles of the International Federation of Gynecology and Obstetrics (FIGO) staging for vulvar carcinoma, select the most appropriate stage. Your choice must be justified by reference to anatomical compartmentalization and hierarchical extent of disease as used in gynecologic oncology staging, beginning from core definitions about tumor confinement to the primary organ, extension to adjacent perineal structures, regional nodal involvement, and invasion of upper compartments or visceral mucosa.\n\nWhich FIGO stage best fits this case?\n\nA. Stage I\n\nB. Stage II\n\nC. Stage III\n\nD. Stage IVA",
            "solution": "The problem statement is first subjected to validation.\n\n### Step 1: Extract Givens\n- **Patient age**: $62$ years\n- **Diagnosis**: Biopsy-proven squamous cell carcinoma of the vulva\n- **Lesion location**: Centered on the right labia majora\n- **Lesion size**: Approximately $3.2$ $\\mathrm{cm}$ in greatest dimension\n- **Invasion depth**: Stromal invasion deeper than $1$ $\\mathrm{mm}$\n- **Local extension**: Contiguous mucosal extension to the ipsilateral lower third of the vagina\n- **Excluded local extension**: No involvement of the upper vagina, urethral meatus, bladder, rectal mucosa, or pelvic bone\n- **Lesion mobility**: Mobile\n- **Regional lymph node status**: No enlarged inguinofemoral nodes by palpation and ultrasound; sentinel lymph node biopsy is negative for metastasis\n- **Distant metastasis status**: Pelvic magnetic resonance imaging (MRI) confirms no pelvic wall involvement and no distant disease\n\n### Step 2: Validate Using Extracted Givens\nThe problem provides a detailed clinical scenario and asks for the application of a standardized medical classification system, the International Federation of Gynecology and Obstetrics (FIGO) staging for vulvar carcinoma.\n\n1.  **Scientifically Grounded**: The problem is grounded in the established medical fields of oncology and pathology. Squamous cell carcinoma is the most common type of vulvar cancer. The clinical parameters provided (size, depth of invasion, local extension, nodal status) are the standard inputs for the FIGO staging system. The scenario is clinically realistic.\n2.  **Well-Posed**: The problem is well-posed. It supplies all necessary information required to apply the FIGO staging criteria. The question asks for the \"most appropriate stage,\" which implies a unique solution derivable from the provided data and the official staging guidelines.\n3.  **Objective**: The problem statement is composed of objective clinical and pathological findings. It is free from ambiguity, subjectivity, and opinion.\n\nThe problem statement is valid as it is scientifically sound, well-posed, and objective.\n\n### Step 3: Verdict and Action\nThe problem is valid. A solution will now be derived.\n\n### Derivation of Solution\nThe staging of vulvar carcinoma is governed by the FIGO classification system. The most current version is the 2021 FIGO staging for Carcinoma of the Vulva, which is based on pathological findings. The solution will be derived by systematically applying these criteria to the patient's data.\n\nThe FIGO staging system is hierarchical, based on three main components:\n1.  **T**: The extent of the primary **T**umor.\n2.  **N**: The absence or presence and extent of regional lymph **N**ode metastasis.\n3.  **M**: The absence or presence of distant **M**etastasis.\n\nLet's review the relevant FIGO stages (2021) and apply the patient's findings.\n\n**Stage I**: Tumor confined to the vulva. No nodal metastasis.\n- **Stage IA**: Lesions $\\le 2$ cm in size, confined to the vulva or perineum, with stromal invasion $\\le 1.0$ mm.\n- **Stage IB**: Lesions $> 2$ cm in size OR with stromal invasion $> 1.0$ mm, confined to the vulva or perineum.\nThe patient's lesion has extended to the \"lower third of the vagina\". Therefore, the tumor is not confined to the vulva. The criteria for Stage I are not met.\n\n**Stage II**: Tumor of any size with extension to adjacent perineal structures (lower $1/3$ of the urethra, lower $1/3$ of the vagina, anus). No nodal metastasis.\nLet us analyze the patient's data against this definition:\n- **Tumor size**: The patient's tumor is $3.2$ cm. Stage II allows for a tumor of any size. This criterion is met.\n- **Extension**: The problem states \"contiguous mucosal extension to the ipsilateral lower third of the vagina\". The lower $1/3$ of the vagina is explicitly listed as an \"adjacent perineal structure\" in the definition of Stage II disease. This criterion is met.\n- **Nodal status**: The problem states, \"sentinel lymph node biopsy returns negative for metastasis\". Thus, there is no nodal metastasis. This criterion is met.\nAll conditions for Stage II are satisfied.\n\n**Stage III**: Tumor of any size with or without extension to adjacent perineal structures, WITH metastasis to inguinofemoral lymph nodes.\nThe patient's sentinel lymph node biopsy was negative. The defining characteristic of Stage III is the presence of lymph node metastasis. As the patient is node-negative, Stage III is excluded.\n\n**Stage IVA**: Tumor invades other regional structures (upper $2/3$ of the urethra, upper $2/3$ of the vagina, bladder mucosa, rectal mucosa, or is fixed to pelvic bone) OR has fixed or ulcerated inguinofemoral lymph nodes.\nThe problem explicitly states there is \"no involvement of the upper vagina, urethral meatus, bladder, rectal mucosa, or pelvic bone\". The lesion is mobile, and the nodes are not described as fixed or ulcerated. Therefore, the criteria for Stage IVA are not met.\n\nBased on this step-by-step application of the FIGO staging criteria, the patient's disease is correctly classified as Stage II.\n\n### Evaluation of Options\n\n**A. Stage I**\nThis option is **Incorrect**. Stage I disease is, by definition, confined to the vulva (or perineum). This patient's tumor has clearly extended to the lower $1/3$ of the vagina, which is an adjacent structure. This extension immediately precludes a Stage I classification.\n\n**B. Stage II**\nThis option is **Correct**. Stage II is defined as a tumor of any size that has spread to adjacent perineal structures—specifically, the lower $1/3$ of the urethra, lower $1/3$ of the vagina, or the anus—but has not metastasized to the lymph nodes. The patient's clinical presentation fits this definition perfectly: a $3.2$ cm tumor with extension to the lower third of the vagina and a negative sentinel lymph node biopsy.\n\n**C. Stage III**\nThis option is **Incorrect**. The hallmark of Stage III vulvar cancer is the presence of metastasis in the regional (inguinofemoral) lymph nodes. The problem provides definitive evidence of a node-negative status via a negative sentinel lymph node biopsy, which is the standard of care for assessing nodal status in clinically node-negative patients.\n\n**D. Stage IVA**\nThis option is **Incorrect**. Stage IVA disease involves tumor extension to upper-compartment structures (upper $2/3$ of the vagina, bladder mucosa, rectal mucosa) or fixation to bone. The clinical and imaging findings explicitly rule out any such involvement.",
            "answer": "$$\\boxed{B}$$"
        }
    ]
}